Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120 - PubMed (original) (raw)

Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120

J A McKeating et al. Virology. 1992 Dec.

Abstract

We demonstrate that soluble CD4 (sCD4) or a monoclonal antibody (mAb), 39.13g, binding to a conformational epitope of gp120 involved in CD4 binding, and mAbs binding to the V3 domain of gp120, can synergistically neutralize human immunodeficiency virus type I (HIV-1). In contrast, a neutralizing mAb binding to a linear epitope within the CD4 binding domain was unable to exert a synergistic effect in combination with V3 mAbs, suggesting that synergism is dependent on ligands binding to the critical, discontinuous, gp120 residues constituting the CD4 binding site. A number of V3 mAbs showed increased binding to virion gp120 in the presence of sCD4, suggesting a mechanism for the synergistic neutralization. This effect was not observed with recombinant or detergent solubilized viral gp120, suggesting that the oligomeric structure of gp120 on viral particles affects V3 epitope exposure. This hypothesis is supported by the ability of two new V3 mAbs, 8/38c and 8/64b, to only neutralize HIV-1 in the presence of sCD4 or mAb 39.13g; binding studies demonstrate that these mAbs only bind to virion gp120 in the presence of sCD4. Thus, V3 epitope exposure is modulated by the interaction of virion gp120 with ligands specific for the CD4 binding domain and results in enhanced antibody-mediated neutralization.

PubMed Disclaimer

Cited by

Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.
Ketas TJ, Holuigue S, Matthews K, Moore JP, Klasse PJ. Ketas TJ, et al. Virology. 2012 Jan 5;422(1):22-36. doi: 10.1016/j.virol.2011.09.019. Epub 2011 Oct 22. Virology. 2012. PMID: 22018634 Free PMC article.
Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.
Wu X, Sambor A, Nason MC, Yang ZY, Wu L, Zolla-Pazner S, Nabel GJ, Mascola JR. Wu X, et al. Virology. 2008 Oct 25;380(2):285-95. doi: 10.1016/j.virol.2008.07.007. Epub 2008 Sep 18. Virology. 2008. PMID: 18804254 Free PMC article.
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
Haynes BF, Montefiori DC. Haynes BF, et al. Expert Rev Vaccines. 2006 Jun;5(3):347-63. doi: 10.1586/14760584.5.3.347. Expert Rev Vaccines. 2006. PMID: 16827619 Free PMC article. Review.
Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.
Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, Franti M, Schülke N, Binley JM. Crooks ET, et al. Hum Antibodies. 2005;14(3-4):101-13. Hum Antibodies. 2005. PMID: 16720980 Free PMC article.
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. Binley JM, et al. J Virol. 2004 Dec;78(23):13232-52. doi: 10.1128/JVI.78.23.13232-13252.2004. J Virol. 2004. PMID: 15542675 Free PMC article.

Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120 - PubMed (original) (raw)